Judge Finalizes $69 Million ChemoCentryx Settlement
The agreement resolves investor claims concerning safety disclosures for a vasculitis treatment developed by the firm.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust that legal settlements in class-action cases prioritize the interests of investors over attorneys?
A federal judge in California has granted final approval to a $69 million settlement resolving a class-action lawsuit against biotech company ChemoCentryx. The case stemmed from investor claims that the company misrepresented the safety profile of its vasculitis medication.
Why it matters
This settlement closes a long-running legal dispute regarding drug safety disclosures in the biotechnology sector. It highlights the financial stakes for developers when clinical trial data interpretation is challenged by the investor community.
The $69 million total fund allocates $15.2 million for attorneys' fees and $4.9 million for litigation expenses. These legal costs represent approximately 22% of the total settlement value approved by the court.
The players
ChemoCentryx
A biotechnology company focused on developing oral therapies for autoimmune diseases and inflammatory disorders.
Jon S. Tigar
A United States District Judge for the Northern District of California who presided over the class-action proceedings.
The details
The lawsuit centered on allegations that ChemoCentryx overhyped the safety of its drug targeting vasculitis—a condition characterized by the inflammation of blood vessels. Investors who held stock between November 26, 2019, and May 6, 2021, claimed the firm failed to accurately report data. Judge Jon S. Tigar of the US District Court for the Northern District of California signed the order finalizing the settlement agreement.
Timeline
Nov. 26, 2019 - May 6, 2021: Period for class action eligibility.
October 29, 2026: Judge Jon S. Tigar granted final approval of the settlement.
The Tech Race
This settlement follows the litigation pattern set by the Private Securities Litigation Reform Act of 1995 regarding shareholder disputes over clinical trial disclosures. It marks a resolution to claims that challenged the transparency of early-stage biotech research reporting.
Individuals who acquired ChemoCentryx stock during the specified eligibility window may now be eligible for payments from the settlement fund. The court's final approval marks the conclusion of the litigation phase for this specific class action.
The takeaway
This $69 million settlement brings closure to investor claims concerning safety transparency in biotech drug trials. Interested parties should monitor subsequent filings from the court-appointed claims administrator regarding the timeline for disbursement.
Further reading
For more on the intersection of clinical research and market transparency, see our latest coverage in Biotech.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Do you trust that legal settlements in class-action cases prioritize the interests of investors over attorneys?
